Zacks Investment Research Upgrades Merus N.V. (MRUS) to “Hold”
Merus N.V. (NASDAQ:MRUS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company’s bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. “
A number of other research analysts have also weighed in on the company. Royal Bank Of Canada initiated coverage on Merus N.V. in a report on Thursday, September 14th. They set an “outperform” rating and a $28.00 target price for the company. ValuEngine lowered Merus N.V. from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $30.00 target price on shares of Merus N.V. in a report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $30.25.
Shares of Merus N.V. (MRUS) opened at $15.67 on Tuesday. Merus N.V. has a twelve month low of $13.13 and a twelve month high of $33.63.
A hedge fund recently bought a new stake in Merus N.V. stock. Renaissance Technologies LLC bought a new position in Merus N.V. (NASDAQ:MRUS) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 22,500 shares of the biotechnology company’s stock, valued at approximately $549,000. Renaissance Technologies LLC owned about 0.14% of Merus N.V. at the end of the most recent reporting period. 31.52% of the stock is owned by institutional investors.
Merus N.V. Company Profile
Receive News & Ratings for Merus N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.